Physician profile
Devi M Dunker
NPI 1881959971
$1,638.90
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $825 · 2020: $78.84 · 2021: $145 · 2022: $288 · 2023: $303.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $303.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $302.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $219.98 | 2019-2023 | |
| Astellas Pharma US INC | $164.63 | 2019-2022 | |
| Novo Nordisk INC | $163.06 | 2019-2021 | |
| Amgen INC. | $159.58 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $136.55 | 2019-2023 | Jardiance |
| Sanofi-Aventis U.S. LLC | $84.58 | 2019-2023 | |
| Lilly USA, LLC | $81.47 | 2019-2023 | Emgality, Jardiance, Mounjaro |
| Abbott Laboratories | $65.87 | 2021-2023 | Freestyle Libre 2 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $59.56 | 2019-2023 | Xifaxan, Trulance |
| Allergan, INC. | $58.94 | 2019 | |
| Abbvie INC. | $54.59 | 2022-2023 | Qulipta |
| Astrazeneca Pharmaceuticals LP | $49.59 | 2019 | |
| Dexcom, INC. | $46.11 | 2022-2023 | Dexcom G6 Transmitter |
| Genentech USA, INC. | $41.97 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $37.76 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $37.38 | 2023 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $28.20 | 2023 | |
| Janssen Pharmaceuticals, INC | $27.52 | 2019-2022 | |
| Xeris Pharmaceuticals, INC. | $21.21 | 2023 | Gvoke Hypopen |
| Sanofi Pasteur INC. | $19.65 | 2019 | |
| Ironwood Pharmaceuticals, INC | $16.00 | 2019 | |
| Glaxosmithkline, LLC. | $14.98 | 2022 | |
| Merck Sharp & Dohme LLC | $13.82 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $13.06 | 2019 | |
| Biogen, INC. | $11.66 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devi Dunker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.